PubMed Health⌕ Search

Biomedical subjects

A Engman

Publications and source records attributed to A Engman.

2 recordsLinked to original sources

Increased plasma hyaluronan in severe pre-eclampsia and eclampsia.

Pre-eclampsia is a serious multi-system disorder with general endothelial disease, often with a component of hepatic dysfunction. The pathogenesis of preeclampsia is not fully understood, and no specific diagnostic tests are available for early and reliable diagnosis, or for monitoring of the disease process. Hyaluronan is an extracellular matrix polysaccharide present at low concentrations in plasma. Normally, it is rapidly eliminated from the blood by the liver. Increased concentrations of circulating hyaluronan are seen in conditions with impaired hepatic function such as liver cirrhosis, and hyaluronan concentrations have previously been used to evaluate hepatic function in other diseases. In the present study, 11 pregnant women admitted to the intensive care unit with severe pre-eclampsia or eclampsia were studied. As control 31 healthy pregnant women, 18 undergoing vaginal delivery and 13 caesarean section, were included. Plasma hyaluronan was measured before and after delivery. Increased concentrations of plasma hyaluronan were found in the pre-eclampsia group both before (171 (75-586) microg/L (p<0.01)) and after delivery (215 (124-768) microg/L (p<0.001)) (median and inter-quartile range), as compared to both caesarean section (13 (7-28) microg/L before and 28 (18-48) microg/L after delivery) and vaginal delivery healthy controls (12 (8-24) microg/L before and 30 (13 63) microg/L after delivery). In the control groups, a small increase in plasma hyaluronan was seen after delivery, after both caesarean section (p<0.05) and vaginal delivery (p<0.01). In conclusion, plasma hyaluronan is increased in severe pre-eclampsia and eclampsia. The cause of the increase is unknown.

Adult↗

Crystalloid infusion increases plasma hyaluronan.

OBJECTIVE: To investigate the changes in plasma hyaluronan concentrations after intravenous infusion of crystalloid solution in healthy subjects. DESIGN: Crossover, controlled study. SETTING: General intensive care unit in a university hospital. SUBJECTS: Twelve healthy medical students. INTERVENTIONS: Infusion of 1000 mL i.v. Ringer's acetate solution during a 40-min period. MEASUREMENTS AND MAIN RESULTS: Plasma hyaluronan concentrations were measured before, during, and after infusion, and under the same conditions without the infusion in a separate session. Hemoglobin, hematocrit, and serum albumin concentrations were measured before and after infusion. Plasma volume at baseline and the volume of Ringer's acetate retained in the intravascular space after infusion were calculated. Plasma hyaluronan values increased from baseline mean of 12 +/- 5.8 (SD) to 20 +/- 13.1 micrograms/L (p < .01) at 30 mins and 25 +/- 13.0 micrograms/L (p < .001) at 40 mins after start of the infusion. Plasma hyaluronan concentrations peaked at 10 mins after the end of the infusion: 27 +/- 13.9 micrograms/L (p < .001). No changes in plasma hyaluronan concentrations were seen during the control period. A volume of 230 to 250 mL of Ringer's acetate solution was calculated to be retained within the intravascular space. CONCLUSIONS: Infusion of crystalloid solution increases plasma hyaluronan, probably through a washout of interstitial hyaluronan by way of increased lymph flow. The consequences of the interstitial loss of hyaluronan on tissue function are unknown.

Adult↗